Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.

    Article  CAS  Google Scholar 

  2. Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–7.

    Article  Google Scholar 

  3. da Costa WL Jr, Tran Cao HS, Massarweh NN. Neoadjuvant treatment for patients with localized pancreatic adenocarcinoma: are we there yet? JAMA Oncol. 2020;6(8):1163–4.

    Article  Google Scholar 

  4. Dahdaleh FS, Naffouje SA, Hanna MH, Salti GI. Impact of neoadjuvant systemic therapy on pancreatic fistula rates following pancreatectomy: a population-based propensity-matched analysis. J Gastrointest Surg. Epub 6 Apr 2020. https://doi.org/10.1007/s11605-020-04581-y.

  5. Kamarajah SK, Naffouje S, Salti GI, Dahdaleh F. Neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma is associated with lower post-pancreatectomy readmission rates: a population-based cohort study. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-020-09470-x.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of HPB and Transplant Surgery, The Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, UK

    Sivesh K. Kamarajah

  2. Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, Newcastle, UK

    Sivesh K. Kamarajah

  3. Department of Surgical Oncology, Edward-Elmhurst Health, Naperville, IL, USA

    Fadi Dahdaleh

Authors
  1. Sivesh K. Kamarajah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fadi Dahdaleh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sivesh K. Kamarajah.

Ethics declarations

DISCLOSURES

Sivesh K. Kamarajah and Fadi Dahdaleh declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamarajah, S.K., Dahdaleh, F. ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?. Ann Surg Oncol 28, 1906–1907 (2021). https://doi.org/10.1245/s10434-020-09472-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-09472-9

Search

Navigation